New GUARDIAN data demonstrates strong parent participation, consistent sequencing performance across diverse ancestries and actionable insights for newborns and families Data from BRIDGES-NBS shows an expert-informed approach to broadening the number of actionable conditions appropriate for gNBS
New tools make genomic testing easier from ordering through results, helping pediatricians confidently integrate genomics into routine care GAITHERSBURG, Md. --(BUSINESS WIRE)--Oct. 2, 2026-- GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today
NPC GenomeComplete to identify children who might otherwise remain undiagnosed through broad NPC-specific eligibility criteria, comprehensive genomic testing and expert diagnostic support GAITHERSBURG, Md. --(BUSINESS WIRE)--Sep. 9, 2026-- GeneDx, the leader in rare disease diagnosis and improving
Recognition highlights GeneDx’s leadership in moving genomic medicine to the forefront of healthcare GAITHERSBURG, Md. --(BUSINESS WIRE)--Sep. 1, 2026-- GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced Katherine Stueland, CEO of
Published in Genetics in Medicine, study shows broad inpatient implementation of rapid genome sequencing significantly increased diagnostic rates and reduced time to diagnosis Children experiencing faltering growth saw striking 63% diagnostic yield GAITHERSBURG, Md. --(BUSINESS WIRE)--Aug.
New offering integrates virtual clinicians to create a scalable channel to increase availability of GeneDx exome testing for eligible children facing specialty-care barriers GAITHERSBURG, Md. --(BUSINESS WIRE)--Aug. 11, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving
GAITHERSBURG, Md. --(BUSINESS WIRE)--Aug. 6, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: Canaccord Genuity 46th Annual Growth
Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue Reported exome and genome volume growth of 32% year-over-year Reported adjusted gross margin (1) of 70% and adjusted net income (1) of $0.4 million Reiterating full year 2026 revenue
GAITHERSBURG, Md. --(BUSINESS WIRE)--Jul. 16, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the second quarter of 2026 after the market closes on Monday, August 3, 2026.
Former Quest Diagnostics leader joins to fuel operational and commercial execution GAITHERSBURG, Md. --(BUSINESS WIRE)--Jun. 16, 2026-- GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced the appointment of Mark Gardner